The AOC1 Knockout A-549 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population derived from human A-549 lung adenocarcinoma epithelial cells, engineered to disrupt the AOC1 gene and establish a loss-of-function model for diamine oxidase. This polyclonal knockout pool is generated via ribonucleoprotein-mediated gene disruption without selection for single-cell clones, providing a mixed population that retains genetic heterogeneity while uniformly abolishing AOC1 function. The resulting polyclonal knockout cells serve as a versatile tool for investigating diamine and polyamine metabolism in a malignant lung epithelial background.
The host A-549 cell line was originally established from the lung adenocarcinoma tissue of a 58-year-old Caucasian male and harbors a KRAS G12S driver mutation, conferring oncogenic signaling dependencies. These adherent epithelial cells are widely employed as a model for pulmonary adenocarcinoma, pulmonary epithelial barrier function, and xenobiotic metabolism, showcasing relevant characteristics such as surfactant production, tight junction formation, and cytochrome P450 enzyme activity. The KRAS-mutant background renders the A-549 cells particularly suitable for studying oncogenic signaling crosstalk with metabolic and inflammatory networks.
AOC1 encodes a copper-containing topaquinone-dependent amine oxidase that catalyzes the oxidative deamination of diamines including histamine and putrescine, producing imidazole acetaldehyde and ammonia while decreasing local polyamine levels. The enzymatic activity of AOC1 is dependent on its interaction with copper ions and the covalently bound topaquinone cofactor. Expression of AOC1 is regulated by upstream factors such as cortisol, interleukin-4 (IL-4), interleukin-13 (IL-13), and tumor necrosis factor (TNF), linking it to inflammatory and stress signaling cascades. Downstream, loss of AOC1 function leads to accumulation of histamine and putrescine, impaired generation of histamine degradation products, and potential dysregulation of p21-mediated cell cycle arrest and apoptosis. Additionally, altered putrescine levels impact polyamine homeostasis, involving spermidine and spermine pathways, and aldehyde dehydrogenase-mediated detoxification of imidazole acetaldehyde may be affected.
Within the A-549 cellular context, CRISPR/Cas9-mediated disruption of AOC1 abrogates diamine oxidase activity, resulting in elevated intracellular and extracellular histamine concentrations and perturbed polyamine pools. This metabolic shift is anticipated to alter epithelial proliferation, apoptosis, and inflammatory responses, since histamine is a well-established mediator of allergic and inflammatory processes, and polyamines are critical for cell growth. The KRAS-mutant background may further sensitize these cells to histamine-driven or polyamine-dependent oncogenic signals, enabling dissection of how amine metabolism intersects with lung adenocarcinoma progression and barrier dysfunction. Consequently, the knockout model permits interrogation of AOC1??s roles in modulating the tumor microenvironment and epithelial homeostasis.
This polyclonal knockout cell product is ideally suited for investigating histamine and polyamine metabolism in lung cancer, facilitating mechanistic studies using diamine oxidase activity assays, histamine ELISA, and putrescine LC-MS quantification. It supports drug screening efforts for diamine oxidase modulators and enables functional analysis of epithelial barrier integrity, allergic response modeling, and inflammatory signaling. Researchers can also employ immunofluorescence, Western blotting for AOC1, cell proliferation MTT assays, apoptosis Annexin V/FACS assays, and wound healing assays to characterize phenotypic outcomes. The interactive effects of cortisol, IL-4, IL-13, and TNF on AOC1-mediated pathways can be systematically explored in this model. For further details, please contact Ascent Research.
